Literature DB >> 31202110

Diversity and antibiotic resistance among Escherichia coli populations in hospital and community wastewater compared to wastewater at the receiving urban treatment plant.

Erik Paulshus1, Inger Kühn2, Roland Möllby2, Patricia Colque2, Kristin O'Sullivan3, Tore Midtvedt2, Egil Lingaas4, Rune Holmstad5, Henning Sørum3.   

Abstract

Bacterial diversity and antimicrobial resistance patterns among the indicator organism Escherichia coli were monitored in wastewater samples collected over one year from a hospital (HW), a community (CW) and the receiving urban (UW) wastewater treatment plant (WWTP). We compared levels of antibiotic resistance in the different types of wastewater, and identified whether resistant strains were endemic in the wastewater system. If so, implementation of local treatment at certain resistance hotspots (e.g. hospital outlets) could be used to decrease the amount of resistant bacteria in the wastewater. E. coli from HW (n = 2644), CW (n = 2525) and UW (n = 2693) were analyzed by biochemical phenotyping (PhenePlate System) and antimicrobial susceptibility testing to nine antibiotics (AREB System). The phenotypic diversities of the total E. coli populations were similar for all three sites (Simpson's Diversity index, Di = 0.973), however for individual samples, HW showed low diversities (Median Di = 0.800) and the E. coli flora was often dominated by strains that may have originated from the fecal flora of single individuals. The diversities in CW samples was higher (Median Di = 0.936), and UW samples showed similar diversities as the whole collection of isolates (Median Di = 0.971). Resistance to at least one of the nine antibiotics was observed in 45% of the HW isolates, 44% of CW isolates, and 33% of UW isolates. Resistance to gentamicin and chloramphenicol was uncommon (3.2 and 5.3%, respectively), whereas resistance to tetracycline and ampicillin was most common (24% and 31%, respectively). Extended-spectrum beta-lactamase-producing E. coli (ESBL-EC) were more common in HW (11.5%) and in CW (6.9%) compared to UW (3.7%). A high diversity (Di = 0.974) was observed among ESBL-EC isolates from UW (n = 99), indicating absence of any clonal structure among these isolates. Common PhP types of ESBL-EC often dominated in each HW sample, but were not identified across different samples, whereas ESBL-EC in CW showed low diversity (Di = 0.857) and were dominated by a specific PhP type that was found across almost all CW samples. The antibiotic resistance rates were highest in hospital wastewater, but surprisingly they were also high in the studied community wastewater, compared to the urban wastewater. The relative contribution of HW seemed low in terms of dissemination of antibiotic resistant bacteria to the WWTP.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  AREB; Extended spectrum beta-lactamase; Indicator bacteria; PhP typing; Surveillance; Wastewater transport infrastructure

Mesh:

Substances:

Year:  2019        PMID: 31202110     DOI: 10.1016/j.watres.2019.05.102

Source DB:  PubMed          Journal:  Water Res        ISSN: 0043-1354            Impact factor:   11.236


  10 in total

1.  Prevalence of Antibiotic-Resistant Bacteria ESKAPE among Healthy People Estimated by Monitoring of Municipal Wastewater.

Authors:  Masateru Nishiyama; Susan Praise; Keiichi Tsurumaki; Hiroaki Baba; Hajime Kanamori; Toru Watanabe
Journal:  Antibiotics (Basel)       Date:  2021-04-26

2.  Repeated Isolation of Extended-Spectrum-β-Lactamase-Positive Escherichia coli Sequence Types 648 and 131 from Community Wastewater Indicates that Sewage Systems Are Important Sources of Emerging Clones of Antibiotic-Resistant Bacteria.

Authors:  Erik Paulshus; Kaisa Thorell; Jessica Guzman-Otazo; Enrique Joffre; Patricia Colque; Inger Kühn; Roland Möllby; Henning Sørum; Åsa Sjöling
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

3.  Multidrug-Resistant Bacteria Isolated from Different Aquatic Environments in the North of Spain and South of France.

Authors:  Lara Pérez-Etayo; David González; José Leiva; Ana Isabel Vitas
Journal:  Microorganisms       Date:  2020-09-16

4.  Enteric bacterial pathogens and their antibiotic-resistant patterns from the environmental sources in different regions of Ethiopia: A laboratory-based cross-sectional study.

Authors:  Chalachew Yenew Denku; Argaw Ambelu; Getnet Mitike
Journal:  Health Sci Rep       Date:  2022-03-02

5.  Prevalence, diversity of diarrhoeagenic Escherichia coli and associated risk factors in well water  in Ile-Ife, Southwestern Nigeria.

Authors:  Babatunde Odetoyin; Olawumi Ogundipe; Adebola Onanuga
Journal:  One Health Outlook       Date:  2022-02-08

6.  Similarities in Virulence and Extended Spectrum Beta-Lactamase Gene Profiles among Cefotaxime-Resistant Escherichia coli Wastewater and Clinical Isolates.

Authors:  Elizabeth Liedhegner; Brandon Bojar; Rachelle E Beattie; Caitlin Cahak; Krassimira R Hristova; Troy Skwor
Journal:  Antibiotics (Basel)       Date:  2022-02-17

7.  Persistence of Antibiotic-Resistant Escherichia coli Strains Belonging to the B2 Phylogroup in Municipal Wastewater under Aerobic Conditions.

Authors:  Hui Xie; Yoshitoshi Ogura; Yoshihiro Suzuki
Journal:  Antibiotics (Basel)       Date:  2022-02-04

8.  Monitoring Carbapenem-Resistant Enterobacterales in the Environment to Assess the Spread in the Community.

Authors:  Taro Urase; Saki Goto; Mio Sato
Journal:  Antibiotics (Basel)       Date:  2022-07-08

9.  Evaluating the Role of Wastewaters as Reservoirs of Antibiotic-Resistant ESKAPEE Bacteria Using Phenotypic and Molecular Methods.

Authors:  Syeda Samar Mustafa; Rida Batool; Muhammad Kamran; Hasnain Javed; Nazia Jamil
Journal:  Infect Drug Resist       Date:  2022-09-28       Impact factor: 4.177

10.  Predicting clinical resistance prevalence using sewage metagenomic data.

Authors:  Antti Karkman; Fanny Berglund; Carl-Fredrik Flach; Erik Kristiansson; D G Joakim Larsson
Journal:  Commun Biol       Date:  2020-11-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.